<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nizatidine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nizatidine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nizatidine: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9708" href="/d/html/9708.html" rel="external">see "Nizatidine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10914" href="/d/html/10914.html" rel="external">see "Nizatidine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867713"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Axid;</li>
<li>DOM-Nizatidine;</li>
<li>PMS-Nizatidine [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060591"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>
<li>
<span class="list-set-name">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F202338"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="453d2aa1-ad96-4b87-b798-62f67b898c2e">Gastroesophageal reflux disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, treatment: </b>Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤11 years: Limited data available: 5 mg/kg/dose twice daily; maximum daily dose: 300 mg/<b>day </b>(AAP [Lightdale] 2013; Vandenplas 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 150 mg twice daily; maximum daily dose: 300 mg/<b>day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62e01d35-13bf-41c4-a8f7-40fa6bbbf15d">Esophagitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophagitis, treatment</b>: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤11 years: Limited data available: 5 mg/kg/dose twice daily. Dosing based on a double blind, placebo controlled trial in 26 pediatric patients (treatment group: n=13; age range: 0.5 to 12 years) with mild to moderate esophagitis (Simeone 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 150 mg twice daily; maximum daily dose: 300 mg/<b>day</b></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131253"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Active treatment: Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 50 mL/minute: 150 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute: 150 mg every other day</p></div>
<div class="block dohp drugH1Div" id="F51131254"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F202320"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9708" href="/d/html/9708.html" rel="external">see "Nizatidine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Nizatidine oral solution has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57b2690d-2e6b-47ae-87e7-f6f5ed2ef93f">Erosive esophagitis due to gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis due to</b>
<b>gastroesophageal reflux disease </b>
<b>(alternative agent): Note:</b> Although a labeled indication, H<sub>2</sub>-receptor antagonists (eg, nizatidine) are not preferred for the treatment of erosive esophagitis due to gastroesophageal reflux disease because of the availability of proton pump inhibitors (PPIs) (ACG [Katz 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 150 mg twice daily for up to 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease:</b>
<b>Oral:</b> 150 mg twice daily; duration of therapy depends on symptoms.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2af7f7c-17b6-4ce5-b3f8-76af48f85574">Peptic ulcer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease (duodenal or benign gastric ulcers) (alternative agent): Note:</b> Although a labeled indication, current guidelines recommend PPIs as standard of care for treatment of peptic ulcer disease rather than H<sub>2</sub>-receptor antagonists (eg, nizatidine) (ACG [Laine 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duodenal ulcer, active</i></b>: <b>Oral</b>: 150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Duodenal ulcer, prophylaxis</i>:</b>
<b>Oral</b>: 150 mg once daily at bedtime for up to 1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Gastric ulcer, active</i></b>: <b>Oral:</b> 150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991789"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer's labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Active treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 20 to 50 mL/minute: 150 mg once daily</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;20 mL/minute: 150 mg every other day</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 20 to 50 mL/minute: 150 mg every other day</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;20 mL/minute: 150 mg every 3 days</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Alternate recommendations (Aronoff 2007):</i></p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute: Administer 75% to 100% of normal dose</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 50 mL/minute: 150 mg every 24 to 48 hours</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute: 150 mg every 48 to 72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: 150 mg every 48 to 72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 150 mg every 48 to 72 hours</p></div>
<div class="block doha drugH1Div" id="F50988974"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F202285"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (children and adolescents), vomiting (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (2%), dizziness (5%), irritability (children and adolescents), nervousness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children and adolescents), nasal congestion (children and adolescents), nasopharyngitis (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any population): Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, exfoliative dermatitis, skin rash, urticaria (Yap 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, hyperuricemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (Kassianos 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Nakano 2004), eosinophilia, immune thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice (including mixed hepatocellular), hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Mira-Perceval 1996), hypersensitivity angiitis (Suh 1997), hypersensitivity reaction, serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F202297"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to nizatidine, other H<sub>2</sub> antagonists, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F202282"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> deficiency: Prolonged treatment (≥2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate to severe renal impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p></div>
<div class="block prod-avail drugH1Div" id="F58318794"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Nizatidine oral solution has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F202292"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg/mL (480 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F202278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F202300"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nizatidine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $4.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867714"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Axid: 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg [DSC], 300 mg</p></div>
<div class="block exp drugH1Div" id="F11430199"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 2.5 mg/mL oral solution may be made with capsules and one of three different vehicles (lemon-lime Gatorade®, Ocean Spray® Cran-Grape® juice or V8® 100% vegetable juice). Empty the contents of one 300 mg capsule in a mortar. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well". Stable for 2 days refrigerated.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613441"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food; do not administer or mix capsule contents with apple juice</p></div>
<div class="block adm drugH1Div" id="F46886485"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with or without food.</p></div>
<div class="block sts drugH1Div" id="F25234198"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nizatidine is stable for 48 hours at room temperature when the contents of a capsule are mixed in Gatorade® lemon-lime, Cran-Grape® grape-cranberry drink, V8®, or aluminum- and magnesium hydroxide suspension (approximate concentration 2.5 mg/mL) (Lantz 1990)</p></div>
<div class="block usep drugH1Div" id="F53568054"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Treatment of endoscopically diagnosed esophagitis (erosive and ulcerative) and associated heartburn due to gastroesophageal reflux disease (GERD) (FDA approved in ages ≥12 years and adults); treatment and maintenance therapy of duodenal ulcer (FDA approved in adults); treatment of active benign gastric ulcer (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Treatment and maintenance therapy of duodenal ulcer; treatment of active benign gastric ulcer; treatment of endoscopically diagnosed esophagitis (erosive and ulcerative) and associated heartburn due to gastroesophageal reflux disease (GERD) (All indications: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F202366"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Axid may be confused with Ansaid</p>
<p style="text-indent:-2em;margin-left:4em;">Nizatidine may be confused with tiZANidine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tazac [Australia] may be confused with Tazact brand name for piperacillin/tazobactam [India]; Tiazac brand name for dilTIAZem [US, Canada]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F202352"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F202287"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: Give acalabrutinib capsules 2 hours before a histamine H2 receptor antagonist (H2RA). No action is required if acalabrutinib tablets are coadministered with H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Histamine H2 Receptor Antagonists may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dacomitinib.  Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Histamine H2 Receptor Antagonists may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of a histamine H2 receptor antagonist (H2RA), and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Infigratinib. Histamine H2 Receptor Antagonists may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with histamine receptor antagonists (H2RAs) or other gastric acid-lowering agents. If H2RAs cannot be avoided, administer infigratinib 2 hours before or 10 hours after administration of H2RAs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Histamine H2 Receptor Antagonists may increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor for reduced efficacy if concomitant use with a H2RA is required. Increases in ketoconazole dose may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir.  Management: Administer H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily simultaneously or 12 hours prior to ledipasvir. The effect of administering H2 receptor antagonists at other time intervals is unknown and  not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Histamine H2 Receptor Antagonists may decrease the absorption of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Histamine H2 Receptor Antagonists may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption.  Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Histamine H2 Receptor Antagonists may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib 2 hours before or 10 hours after histamine H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir.  Management: Consider alternatives to this combination for patients taking the Invirase formulation of saquinavir. No action beyond standard clinical care measures is required for patients taking the Fortovase formulation of saquinavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and H2 receptor antagonists should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 10 hours after H2 receptor antagonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Histamine H2 Receptor Antagonists may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F202312"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>
<div class="block pri drugH1Div" id="F202301"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. Nizatidine crosses the placenta (Dicke 1988). Information related to the use of nizatidine in pregnancy is limited; other agents may be preferred (Richter 2005).</p></div>
<div class="block pha drugH1Div" id="F202281"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibition of histamine at H<sub>2</sub>-receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.</p></div>
<div class="block phk drugH1Div" id="F202296"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.8 to 1.5 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 35% to alpha-1 acid glycoprotein </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Partially hepatic; forms metabolites </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: &gt;70% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1 to 2 hours; prolonged with moderate to severe renal impairment </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 0.5 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&gt;90%; ~60% as unchanged drug); feces (&lt;6%)</p></div>
<div class="block phksp drugH1Div" id="F51154903"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Moderate to severe renal impairment decreases clearance and prolongs half-life.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F202303"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Axid | Fixit</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ulxit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nizac | Nizaction | Tacidine | Tazac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Panaxid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Calmaxid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nizaxid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gastrax | Nizax</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Izatax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Axid | Nizalap</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nizatect | Nizatine | Receptoloc | Ulcfree</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Distaxid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nizax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nizatidine Dci | Nizaxid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Axid | Nizatidine almus | Nizatidine arrow | Nizatidine cox | Nizatidine kent | Nizatidine sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Axid | Flexidon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Axid | Naxidin | Naxidin-s</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cronizat | Nizax | Zanizal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Acinon eli lilly | Acinon zeria | Ateminon | Dorusen | Nisatenon | Nisatenon choseido | Nizamerck | Nizanon | Nizatidine alfresa | Nizatidine ohara | Nizatin | Nizatiron | Nizatoric | Tizanon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acitidine | Actidin | Alzatine | Anitidine | Anytidine | Axadin | Axatid | Axid | Axidin | Bicsidin | Bigcidine | Cellnidine | Exad | Exadin | Exatid | Exitidine | Huniz nizatidine | Huons nizatidine | Kenatine | Megatidin | Nacid | Naicid | Nazitine | Neizatin | Newtidine | Newxanthine | Newzantine | Newzatin | Nex | Nitadin | Niza ex | Niza x | Nizad | Nizadine | Nizadinem | Nizant | Nizar | Nizaractine | Nizaridine | Nizatan | Nizaten | Nizatide | Nizatin | Nizatwo | Nizaxid | Nizixid | Samsung nizatidine | Tinza | Zadin | Zanide | Zanitan | Zanitidine | Zanitin | Zastidine | Zatidine | Zatinol | Zenitidine | Zinadine | Zinatine | Zynide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Axid | Fixit</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Panaxid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Axid | Nizatidinum</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Axid | Ulcid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nizax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nizaxid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fixit</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Axid | Fixit</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Axid | Nyzant</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acid reducer | Tazac</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Axid</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Farnatyl | Kagawas | Mezagastro | Mizatin | Nizastric</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Antizid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15085026">
<a name="15085026"></a>Abdel-Rahman SM, Johnson FK, Connor JD, et al, "Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine," <i>J Pediatr Gastroenterol Nut</i>, 2004, 38(4):442-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/15085026/pubmed" id="15085026" target="_blank">15085026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12616667">
<a name="12616667"></a>Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, et al, "The Bioequivalence of Nizatidine (Axid) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared With Capsule," <i>J Clin Pharmacol</i>, 2003, 43(2):148-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/12616667/pubmed" id="12616667" target="_blank">12616667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17413923">
<a name="17413923"></a>American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. <i>Anesthesiology</i>. 2007;106(4):843-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/17413923/pubmed" id="17413923" target="_blank">17413923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2892261">
<a name="2892261"></a>Callaghan JT, Bergstrom RF, Rubin A, et al, “A Pharmacokinetic Profile of Nizatidine in Man,” <i>Scand J Gastroenterol Suppl</i>, 1987, 136:9-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2892261/pubmed" id="2892261" target="_blank">2892261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <i>Pediatrics</i>. 2006;117(5):e817-e820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD and Wong B, “American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,” <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7769203">
<a name="7769203"></a>Chey WD, Kochman ML, Traber PG, et al, “Possible Nizatidine-Induced Subfulminant Hepatic Failure,” <i>J Clin Gastroenterol</i>, 1995, 20(2):164-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/7769203/pubmed" id="7769203" target="_blank">7769203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2895583">
<a name="2895583"></a>Dicke JM, Johnson RF, Henderson GI, et al. A comparative evaluation of the transport of H<sub>2</sub>-receptor antagonists by the human and baboon placenta. <i>Am J Med Sci</i>. 1988 Mar;295(3):198-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2895583/pubmed" id="2895583" target="_blank">2895583</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fennerty MD and Higbee M, “Drug Therapy of Gastrointestinal Disease,” <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 585-608.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12755836">
<a name="12755836"></a>Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. <i>Aliment Pharmacol Ther</i>, 2003;17(10):1229-1236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/12755836/pubmed" id="12755836" target="_blank">12755836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, “American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,” <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2565456">
<a name="2565456"></a>Kassianos GC. Impotence and nizatidine. <i>Lancet</i>. 1989;1(8644):963. doi:10.1016/s0140-6736(89)92548-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2565456/pubmed" id="2565456" target="_blank">2565456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2013;108(3):308-328. doi:10.1038/ajg.2012.444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2870891">
<a name="2870891"></a>Knadler MP, Bergstrom RF, Callaghan JT, et al, “Nizatidine, An H<sub>2</sub>-Blocker. Its Metabolism and Disposition in Man,” <i>Drug Metab Dispos</i>, 1986, 14(2):175-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2870891/pubmed" id="2870891" target="_blank">2870891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28242110">
<a name="28242110"></a>Lanas A, Chan FKL. Peptic ulcer disease. <i>Lancet</i>. 2017;390(10094):613-624. doi:10.1016/S0140-6736(16)32404-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/28242110/pubmed" id="28242110" target="_blank">28242110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1980576">
<a name="1980576"></a>Lantz MD, Wozniak TJ. Stability of nizatidine in extemporaneous oral liquid preparations. <i>Am J Hosp Pharm</i>. 1990;47(12):2716-2719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/1980576/pubmed" id="1980576" target="_blank">1980576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7826786">
<a name="7826786"></a>Mikawa K, Nishina K, Maekawa N, et al, “Effects of Oral Nizatidine on Preoperative Gastric Fluid pH and Volume in Children,” <i>Br J Anaesth</i>, 1994, 73(5):600-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/7826786/pubmed" id="7826786" target="_blank">7826786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8613644">
<a name="8613644"></a>Mira-Perceval JL, Ortiz JL, Sarrió F, et al. Nizatidine anaphylaxis. <i>J Allergy Clin Immunol</i>. 1996;97(3):855-856. doi:10.1016/s0091-6749(96)80165-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/8613644/pubmed" id="8613644" target="_blank">8613644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15235935">
<a name="15235935"></a>Nakano T, Kuroiwa T, Tsumita Y, et al. Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient. <i>Clin Exp Nephrol</i>. 2004;8(2):160-162. doi:10.1007/s10157-003-0274-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/15235935/pubmed" id="15235935" target="_blank">15235935</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nizatadine capsules [prescribing information]. Mahwah, NJ: Glenmark Generics Inc USA; November 2018.</div>
</li>
<li>
<div class="reference">
                  Nizatidine oral solution [prescribing information]. Glasgow, KY: Amneal Pharmaceuticals; March 2009.</div>
</li>
<li>
<div class="reference">
                  Nizatidine solution [prescribing information]. Bridgewater, NJ: Gemini Laboratories, LLC; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15922820">
<a name="15922820"></a>Orenstein SR, Gremse DA, Pantaleon CD, Kling DF, Rotenberg KS. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. <i>Clin Ther</i>. 2005;27(4):472-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/15922820/pubmed" id="15922820" target="_blank">15922820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16225482">
<a name="16225482"></a>Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/16225482/pubmed" id="16225482" target="_blank">16225482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11192451">
<a name="11192451"></a>Rudolph CD, Mazur LJ, Liptak GS, et al, “Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(Suppl 2):1-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/11192451/pubmed" id="11192451" target="_blank">11192451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9226527">
<a name="9226527"></a>Simeone D, Caria MC, Miele E, et al, “Treatment of Childhood Peptic Esophagitis: A Double-Blind Placebo-Controlled Trial of Nizatidine,” <i>J Pediatr Gastroenterol Nutr</i>, 1997, 25(1):51-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/9226527/pubmed" id="9226527" target="_blank">9226527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9217573">
<a name="9217573"></a>Suh JG, Oleksowicz L, Dutcher JP. Leukocytoclastic vasculitis associated with nizatidine therapy. <i>Am J Med</i>. 1997;102(2):216-217. doi:10.1016/s0002-9343(96)00356-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/9217573/pubmed" id="9217573" target="_blank">9217573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11850662">
<a name="11850662"></a>Sullivan TJ, Reese JH, Buchmann KA, et al, “Bioavailability Study of Nizatidine When Administered in Food,” <i>Am J Ther</i>, 1995, 2:275-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/11850662/pubmed" id="11850662" target="_blank">11850662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9678811">
<a name="9678811"></a>Talley NJ, Chang FY, Wyatt JM, et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. <i>Aliment Pharmacol Ther</i>. 1998;12(6):527-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/9678811/pubmed" id="9678811" target="_blank">9678811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19745761">
<a name="19745761"></a>Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/19745761/pubmed" id="19745761" target="_blank">19745761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2895125">
<a name="2895125"></a>Vargas R, Ryan J, McMahon G, et al, “Pharmacokinetics and Pharmacodynamics of Oral Nizatidine,” <i>J Clin Pharmacol</i>, 1988, 28(1):71-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2895125/pubmed" id="2895125" target="_blank">2895125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1679316">
<a name="1679316"></a>Yap CK, Chong YY, Chia SC, Fock KM. Nizatidine versus cimetidine in the treatment of duodenal ulcers. <i>Ann Acad Med Singap</i>. 1991;20(2):241-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/1679316/pubmed" id="1679316" target="_blank">1679316</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12649 Version 296.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
